Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.
Division of Cardiology, Creighton University School of Medicine, Omaha, NE, USA.
Indian Heart J. 2021 Mar-Apr;73(2):161-168. doi: 10.1016/j.ihj.2021.01.006. Epub 2021 Jan 7.
The initial enthusiasm for thrombectomy during percutaneous coronary intervention (PCI) of ST-elevation myocardial infarction (STEMI) patients has given way to restraint. There has been some limited interest whether it is beneficial in a few selected subgroups. Hence, we performed a network meta-analysis to compare conventional PCI (cPCI), Aspiration or manual thrombectomy (AT) and Mechanical thrombectomy (McT) for clarification.
Electronic databases were searched for randomized studies that compared AT, McT, or cPCI. A network meta-analysis was performed and odd's ratio (OR) with 95% confidence intervals was generated for major adverse cardiac events (MACE), mortality, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST), stroke, left ventricular ejection fraction (LVEF), myocardial blush grade (MBG) and ST segment resolution (STR).
A total of 43 randomized trials (n = 26,682) were included. The risk of MACE (OR 0.86 95% CI 0.73-1.00), Mortality (OR 0.85 95% CI 0.73-0.99), MI (OR 0.65, 95% CI: 0.44-0.95) and TVR (OR 0.86, 95% CI: 0.74-1.00) were lower with AT compared to cPCI. The risk of ST and stroke was no different with the use of adjunctive AT. MBG, STR, and LVEF improved with the use of AT while the infarct size was no different in the two groups.
Our comprehensive network meta-analysis suggests conflicting outcomes with AT. While Mortality, MACE, MI seem better, there is a suggestion that, Stroke and ST might be worse. Whether AT can still be pursued in any select cases should be further scrutinized.
经皮冠状动脉介入治疗(PCI)治疗 ST 段抬高型心肌梗死(STEMI)患者时,最初对血栓切除术的热情已经消退,人们对其在少数选定亚组中是否有益产生了一些有限的兴趣。因此,我们进行了一项网络荟萃分析,以比较常规 PCI(cPCI)、抽吸或手动血栓切除术(AT)和机械血栓切除术(McT)。
检索了比较 AT、McT 或 cPCI 的随机研究的电子数据库。进行了网络荟萃分析,并生成了主要不良心脏事件(MACE)、死亡率、心肌梗死(MI)、靶血管血运重建(TVR)、支架血栓形成(ST)、卒中、左心室射血分数(LVEF)、心肌染色分级(MBG)和 ST 段缓解(STR)的比值比(OR)和 95%置信区间。
共纳入 43 项随机试验(n=26682)。与 cPCI 相比,AT 降低了 MACE(OR 0.86,95%CI:0.73-1.00)、死亡率(OR 0.85,95%CI:0.73-0.99)、MI(OR 0.65,95%CI:0.44-0.95)和 TVR(OR 0.86,95%CI:0.74-1.00)的风险。联合使用 AT 并不会增加 ST 和卒中的风险。使用 AT 可改善 MBG、STR 和 LVEF,而两组的梗死面积无差异。
我们的综合网络荟萃分析表明,AT 的结果存在冲突。虽然死亡率、MACE 和 MI 似乎更好,但有迹象表明,卒中和 ST 可能更差。是否仍可在某些特定情况下使用 AT 仍需进一步研究。